Shah, Sanjiv J.

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 2,884

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine

Amyloidosis: Diagnosis, Treatment, OutcomesAlzheimer's disease research and treatments

Cited by 2,857

Spironolactone for heart failure with preserved ejection fraction

Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine

Heart Failure Treatment and ManagementHormonal Regulation and Hypertension

Cited by 2,809

Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine

Heart Failure Treatment and ManagementRenin-Angiotensin System Studies

Cited by 2,430

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,669

Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction

Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., Bonow, R. O., Huang, C.-C., & Deo, R. C. (2015) · Circulation

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,157

Fully Automated Echocardiogram Interpretation in Clinical Practice: Feasibility and Diagnostic Accuracy

Zhang, J., Gajjala, S., Agrawal, P., Tison, G. H., Hallock, L. A., Beussink-Nelson, L., Lassen, M. H., Fan, E., Aras, M. A., Jordan, C., et al. (2018) · Circulation

Artificial Intelligence in Healthcare and EducationCardiovascular Function and Risk Factors

Cited by 1,006

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap

Shah, S. J., Kitzman, D. W., Borlaug, B. A., van Heerebeek, L., Zile, M. R., Kass, D. A., & Paulus, W. J. (2016) · Circulation

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,003

SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · The Lancet

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 996

Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., et al. (2024) · New England Journal of Medicine

Heart Failure Treatment and ManagementHormonal Regulation and Hypertension

Cited by 893

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 758

Heart Failure With Preserved Ejection Fraction

Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 742

Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF

Shah, S. J., Lam, C. S. P., Svedlund, S., Saraste, A., Hage, C., Tan, R.-S., Beussink-Nelson, L., Ljung Faxén, U., Fermer, M. L., Broberg, M. A., et al. (2018) · European Heart Journal

Cardiovascular Function and Risk FactorsCardiac Imaging and Diagnostics

Cited by 656

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial

Nassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Tang, F., Khariton, Y., Malik, A. O., Khumri, T., Umpierrez, G., et al. (2021) · Nature Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 618

The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF

Savji, N., Meijers, W. C., Bartz, T. M., Bhambhani, V., Cushman, M., Nayor, M., Kizer, J. R., Sarma, A., Blaha, M. J., Gansevoort, R. T., et al. (2018) · JACC: Heart Failure

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 499

Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone

Shah, A. M., Claggett, B., Sweitzer, N. K., Shah, S. J., Anand, I. S., Liu, L., Pitt, B., Pfeffer, M. A., & Solomon, S. D. (2015) · Circulation

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 478

Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary

Shah, S. J., Borlaug, B. A., Kitzman, D. W., McCulloch, A. D., Blaxall, B. C., Agarwal, R., Chirinos, J. A., Collins, S., Deo, R. C., Gladwin, M. T., et al. (2020) · Circulation

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 436

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

Butler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., et al. (2024) · The Lancet

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 386

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study

Pieske, B., Maggioni, A. P., Lam, C. S. P., Pieske-Kraigher, E., Filippatos, G., Butler, J., Ponikowski, P., Shah, S. J., Solomon, S. D., Scalise, A.-V., et al. (2017) · European Heart Journal

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 366

Whole-genome association study identifies STK39 as a hypertension susceptibility gene

Wang, Y., O'Connell, J. R., McArdle, P. F., Wade, J. B., Dorff, S. E., Shah, S. J., Shi, X., Pan, L., Rampersaud, E., Shen, H., et al. (2009) · Proceedings of the National Academy of Sciences

Blood Pressure and Hypertension StudiesGenetic Associations and Epidemiology

Cited by 298

Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction

Thenappan, T., Shah, S. J., Gomberg-Maitland, M., Collander, B., Vallakati, A., Shroff, P., & Rich, S. (2011) · Circulation Heart Failure

Pulmonary Hypertension Research and TreatmentsHeart Failure Treatment and Management

Cited by 289

Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms

Goto, S., Mahara, K., Beussink-Nelson, L., Ikura, H., Katsumata, Y., Endo, J., Gaggin, H. K., Shah, S. J., Itabashi, Y., MacRae, C. A., et al. (2021) · Nature Communications

Amyloidosis: Diagnosis, Treatment, OutcomesECG Monitoring and Analysis

Cited by 245

Quality of Life in Heart Failure with Preserved Ejection Fraction: Importance of Obesity, Functional Capacity, and Physical Inactivity

Reddy, Y. N. V., Rikhi, A., Obokata, M., Shah, S. J., Lewis, G. D., AbouEzzedine, O. F., Dunlay, S., McNulty, S., Chakraborty, H., Stevenson, L. W., et al. (2020) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiovascular and exercise physiology

Cited by 243

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

Borlaug, B. A., Kitzman, D. W., Davies, M. J., Rasmussen, S., Barros, E., Butler, J., Einfeldt, M. N., Hovingh, G. K., Møller, D. V., Petrie, M. C., et al. (2023) · Nature Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 215